论文部分内容阅读
目的探究恶性腹腔积液分别采取抗肿瘤药物奈达铂与顺铂腹腔灌洗化疗的临床疗效及安全性差异,并为该病临床策略的制定提供数据支持。方法选取该院2010年3月—2013年10月收治的78例恶性腹腔积液患者,利用随机数字表法进行分组,分别设为观察组和对照组,每组各39例。其中观察组开展奈达铂腹腔灌注化疗,对照组开展顺铂腹腔灌注化疗。记录二组患者在治疗期间不良反应发生情况及腹腔积液控制水平。结果二组在腹腔积液消退方面差异无统计学意义(P>0.05)。观察组胃肠道反应发生率低于对照组(P<0.05)。二组在肾功能损伤、骨髓移植及肝功能损伤方面差异无统计学意义(P>0.05)。结论奈达铂与顺铂灌注化疗方案在控制恶性腹腔积液腹方面效果相当,且安全性可,值得在临床上进行推广应用。
Objective To investigate the clinical efficacy and safety differences of antitumor drug nedaplatin and cisplatin intraperitoneal lavage chemotherapy in malignant ascites and to provide data support for the clinical strategy of the disease. Methods Seventy-eight patients with malignant ascites were selected from March 2010 to October 2013 in our hospital. Patients were divided into observation group and control group by random number table method, with 39 cases in each group. The observation group received nedaplatin intraperitoneal chemotherapy, and the control group received cisplatin intraperitoneal chemotherapy. Record two groups of patients during treatment of adverse reactions and control of ascites. Results There was no significant difference between the two groups in the regression of ascites (P> 0.05). The incidence of gastrointestinal reaction in the observation group was lower than that in the control group (P <0.05). There was no significant difference between the two groups in terms of renal dysfunction, bone marrow transplantation and liver injury (P> 0.05). Conclusion Nedaplatin and cisplatin infusion chemotherapy regimen in the control of malignant ascites abdominal effect, and safety, it is worth in the clinical application.